What is Leerink Partnrs’ Estimate for CNTA FY2025 Earnings?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) – Stock analysts at Leerink Partnrs lowered their FY2025 earnings per share estimates for shares of Centessa Pharmaceuticals in a report released on Wednesday, November 5th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn ($1.39) per share for the year, down from their previous forecast of ($1.37). The consensus estimate for Centessa Pharmaceuticals’ current full-year earnings is ($1.60) per share. Leerink Partnrs also issued estimates for Centessa Pharmaceuticals’ FY2026 earnings at ($1.61) EPS, FY2027 earnings at ($1.68) EPS and FY2028 earnings at ($1.88) EPS.

Several other brokerages also recently commented on CNTA. Chardan Capital reiterated a “buy” rating and issued a $30.00 target price on shares of Centessa Pharmaceuticals in a report on Tuesday, August 12th. Stephens started coverage on Centessa Pharmaceuticals in a research report on Tuesday, October 28th. They issued an “overweight” rating and a $35.00 price target on the stock. Lifesci Capital raised Centessa Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, September 3rd. Wall Street Zen upgraded Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. Finally, Truist Financial set a $30.00 price target on Centessa Pharmaceuticals in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $32.56.

Centessa Pharmaceuticals Trading Down 3.1%

Shares of NASDAQ:CNTA opened at $22.12 on Monday. The company has a current ratio of 10.56, a quick ratio of 10.57 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $2.96 billion, a PE ratio of -12.09 and a beta of 1.56. Centessa Pharmaceuticals has a 1 year low of $9.60 and a 1 year high of $25.42. The firm has a fifty day moving average price of $22.30 and a 200 day moving average price of $17.16.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02).

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after acquiring an additional 3,194 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $47,000. Bank of New York Mellon Corp bought a new stake in shares of Centessa Pharmaceuticals during the 1st quarter worth approximately $147,000. Fox Run Management L.L.C. acquired a new stake in shares of Centessa Pharmaceuticals in the 1st quarter valued at approximately $160,000. Finally, Vestal Point Capital LP bought a new position in shares of Centessa Pharmaceuticals in the first quarter valued at $214,000. 82.01% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, General Counsel Iqbal J. Hussain sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $20.01, for a total transaction of $400,200.00. Following the transaction, the general counsel owned 105,386 shares in the company, valued at $2,108,773.86. This represents a 15.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mario Alberto Accardi sold 8,172 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $21.40, for a total transaction of $174,880.80. Following the completion of the transaction, the insider directly owned 197,394 shares in the company, valued at $4,224,231.60. This trade represents a 3.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 145,964 shares of company stock valued at $3,169,861. 7.09% of the stock is currently owned by corporate insiders.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.